Haptoglobin-related protein as a serum marker in malignant lymphoma

Ron Epelbaum, Channa Shalitin, Ruth Segal, Clari Valansi, Ida Arselan, David Faraggi, Michelle Leviov, Menahem Ben-Shahar, Nissim Haim

Research output: Contribution to journalArticlepeer-review


A novel serum 21 kDa haptoglobin-related protein (Hpr) was investigated in patients with malignant lymphoma, to evaluate its correlation with clinical and histologic features at presentation and its possible role as a tumor marker for patient outcome. One hundred fifty eight serum samples were taken from 88 patients with non-Hodgkin's lymphoma (n=58) and Hodgkin's disease (n=30) at presentation and in the course of follow-up. Sera from 61 healthy volunteers served as normal controls. Serum Hpr levels in the lymphoma patients (median 430 x 103 u/ml, range 0-4000 x 103) were significantly higher than in the control group (median 68 x 103 u/ml, range 0-180 x 103) (p=0.0001). Higher median Hpr values were detected in patients with advanced disease (p=0.013), 'B' symptoms (p=0.029) and in males (p=0.053). There was also a significant correlation between Hpr and erythrocyte sedimentation rate (p=0.028). Serial determinations showed a significant decrease of the initial Hpr values obtained after treatment in 41 patients, 38 of whom achieved complete remission. In the follow-up period additional Hpr measurements were taken from 17 patients. Three of them eventually relapsed, and showed increased Hpr levels at the time of relapse. Hpr levels remained low in 11 of 14 patients who maintained complete remission, and increased in three. In conclusion, serum Hpr is a new serum tumor marker of potential use in the clinical setting of lymphoma.

Original languageEnglish
Pages (from-to)271-276
Number of pages6
JournalPathology and Oncology Research
Issue number4
StatePublished - 1998

Bibliographical note

Funding Information:
The outlook for lymphoma patients is heterogeneous. Although a substantial proportion of patients achieves complete remission, some of them may either do not response to treatment or experience relapse. The evaluation of the effectiveness of induction therapy is important, Received: August 12, 1998; accepted: Sept 30, 1998 Correspondence: Dr. Ron EPELBAUM, Department of Oncology, Rambam Medical Center, Haifa 31096, Israel; tel: 972-4-8543128, fax: 972-4-8542929 *This work is dedicated to the memory of Dr. Arie H. Bartal, a dedicated oncologist and friend. This work was supported by Chemotech Thechnologies Ltd., by grant no. 3676 from the Chief Scientist's Office of the Ministry of Health, Israel, and by the Fund for Promotion of Research in the Technion.


  • 21-kDa protein
  • Haptoglobin-related protein
  • Lymphoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research


Dive into the research topics of 'Haptoglobin-related protein as a serum marker in malignant lymphoma'. Together they form a unique fingerprint.

Cite this